Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation); (to be eligible, prothrombin time/international normalized ratio [PT INR] should be < 1.4 for patients not on warfarin)
Evidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is permitted, but patients must be on a stable dose.
Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).
Known coagulopathy or bleeding diathesis; those on therapeutic anticoagulation or anti-platelet agent are permitted only after discussing with the study PI
(Bevacizumab-related exclusion) Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation); any history of significant bleeding or thrombosis should be discussed with the study principal investigators (PIs)
History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation); current or recent (within 10 days of study enrollment) use of anticoagulants that, in the opinion of the investigator, would place the subject at significant risk for bleeding; prophylactic use of anticoagulants is allowed
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nNo prior or current evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Participants should not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Serious bleeding diathesis or those who are on therapeutic anticoagulation
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) within 4 weeks of first study dose